Blood-derived biomarkers for brain and spinal cord diseases are urgently needed. The
introduction of highly sensitive immunoassays led to a rapid increase in the number of …

For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …

Timely detection of the pathophysiological changes and cognitive impairment caused by
Alzheimer's disease (AD) is increasingly pressing because of the advent of biomarker …

Importance Glial fibrillary acidic protein (GFAP) is a marker of reactive astrogliosis that
increases in the cerebrospinal fluid (CSF) and blood of individuals with Alzheimer disease …

Although recent clinical trials targeting amyloid-β in Alzheimer's disease have shown
promising results, there is increasing evidence suggesting that understanding alternative …

Introduction Plasma glial fibrillary acidic protein (GFAP) is a marker of astroglial activation
and astrocytosis. We assessed the ability of plasma GFAP to detect Alzheimer's disease …

Background Increasing evidence supports the use of plasma biomarkers of
neurodegeneration and neuroinflammation to screen and diagnose patients with dementia …

Background Plasma assays for the detection of Alzheimer's disease neuropathological
changes are receiving ever increasing interest. The concentration of plasma glial fibrillary …

Discovery and development of clinically useful biomarkers for Alzheimer's disease (AD) and
related dementias have been the focus of recent research efforts. While cerebrospinal fluid …

Objective Reactive astrogliosis is a hallmark of Alzheimer's disease (AD) and frontotemporal
dementia (FTD) but differences between the diseases and time course are unclear. Here, we …